检验医学与临床2018，Vol.15Issue(12)：1711-1715,5.DOI:10.3969／j.issn.1672-9455.2018.12.005
埃克替尼联合化疗与埃克替尼单药在晚期非小细胞肺癌一线治疗中的比较研究
The comparative study of ecotinib combined with chemotherapy and ecotinib monotherapy in the first line treatment of advanced non-small cell lung cancer
摘要
Abstract
Objective To compare the efficacy and safety of hydrochloric acid ecotinib combined with chem-otherapy with ecotinib monotherapy as first-line treatment of advanced non-small cell lung cancer(NSCLC)harbored epidermal grow th factor(EGFR)sensitive mutation(19 exon deletion or 21 exon mutation).Meth-ods 78 cases between January 2013 and December 2015 in the hospital were enrolled in the study.36 cases treated with ecotinib combined with chemotherapy were taken as ecotinib combined with chemotherapy group,42 cases treated with ecotinib monotherapy were taken as ecotinib monotherapy group and the clinical data of NSCLC patients were retrospectively analyzed.There were 19 patients with 19 exon deletion and 17 patients with 21 exon mutation in ecotinib combined with chemotherapy group,29 patients with 19 exon deletion and 13 patients with 21 exon mutation in ecotinib monotherapy group.Results The objective response rate for the ecotinib combined with chemotherapy group was 75.0％,that for ecotinib monotherapy group was 50.0％,and there was a significantly statistical difference between two groups(P＝0.024).Disease control rates for the ecotinib combined with chemotherapy group was 97.2％,that for ecotinib monotherapy group was 95.2％,and there was no statistical difference between groups(P＝0.650).In the ecotinib combined with chemothera-py group,the median progression-free survival time(PFS)was 12.4 months,that in ecotinib monotherapy group was 8.6 months,and the difference was statistically significant(P＜0.05).The median overall survival time(OS)in ecotinib combined with chemotherapy group was 23.3 months,that in the ecotinib monotherapy group was 18.9 months,and the difference was statistically significant(P＝0.037).The results of subgroup analysis showed that for the patients with 19 exon deletion,the PFS was 14.4 months in ecotinib combined with chemotherapy group,9.3 months in ecotinib monotherapy group,and the difference was statistically sig-nificant(P＜0.05).The OS was 24.9 months in ecotinib combined with chemotherapy group and 19.5 months in ecotinib monotherapy group,and the difference was statistically significant(P＝0.032).For the patients with 21 exon mutation,the PFS was 10.4 months in ecotinib combined with chemotherapy group,7.1 months in ecotinib monotherapy group,and the difference was statistically significant(P＝0.004).The OS was 21.8 months in ecotinib combined with chemotherapy group and 18.6 months in ecotinib monotherapy group,and the difference was statistically significant(P＝0.252).Ecotinib combined chemotherapy group had a higher incidence rate of adverse reactions,but most can be tolerated.Conclusion Compared with ecotinib monother-apy group,ecotinib combined with chemotherapy can achieve better curative effect,especially for the patients with 19 exon deletion.Although the ecotinib combined with chemotherapy group had more adverse reactions than ecotinib monotherapy group had,but can be tolerated in general.Ecotinib combined with chemotherapy can be chosen as the first-line treatment for advanced NSCLC harbored EGFR sensitive mutation.关键词
埃克替尼/非小细胞肺癌/获得性耐药Key words
ecotinib/non-small cell lung cancer/acquired drug resistance分类
医药卫生引用本文复制引用
王璐璐,王东林,李禄椿,李艳,吴志鹃,阳丹,马惠文..埃克替尼联合化疗与埃克替尼单药在晚期非小细胞肺癌一线治疗中的比较研究[J].检验医学与临床,2018,15(12):1711-1715,5.基金项目
中国癌症基金会北京希望马拉松专项基金资助项目(LC2016W04). （LC2016W04）
